Scientific Industries (SCND) Q2 2025 earnings summary

Executive summary

• Completed sale of legacy Genie lab products division to OHAUS (Mettler Toledo) for $9.6M plus potential $1.5M earn-out, marking a strategic shift from traditional lab equipment to AI-powered life science platforms and digital bioprocessing solutions.

• Focus now on Vivid automated pill counters, Torbal scales for stable cash flow, and bioprocessing division with upcoming product milestones.

• Transformation aims to address modern challenges in pharmacy productivity and synthetic biology, with a business model shift toward hardware, subscription software, and single-use sensor technology.

• Net loss before income tax was $1.52M for Q2 2025, compared to $1.28M loss in Q2 2024, mainly due to lower revenues and global trade uncertainties.

• Revenues for Q2 2025 decreased 12% year-over-year to $2.33M, with declines in both Benchtop Laboratory Equipment and Bioprocessing Systems segments.

Significant events and developments

• Sale of Genie lab products division finalized, closing a 70-year chapter and enabling a new strategic direction.

• On August 7, 2025, agreement to sell Genie Division assets for $9.6M plus potential $1.5M earn-out, with supply and transition service agreements in place.

• Integration of new team members from OHAUS to ensure continuity for Genie customers and suppliers.

• Filed a new patent for high-precision dispensing technology in shaken systems.

• April 2025 private placement raised $1.55M through sale of stock and warrants.

Segment performance

• Bioprocessing division advanced R&D across all major development tracks, including dissolved oxygen, biomass, pH, and glucose sensing, with several product launches and pilot studies completed.

• Torbal scales division continues to provide predictable cash flows and growth opportunities.

• Vivid pill counter platform focused on machine learning, innovation, and subscription monetization.

• Benchtop segment saw decreased Genie product sales, partially offset by Torbal sales.

• Bioprocessing Systems segment faced order delays and product availability issues.